Exosomes derived from mesenchymal stem cells containing berberine for ulcerative colitis therapy

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Pharmacology

Background:

• Ulcerative colitis (UC) is a chronic inflammatory bowel disease with limited therapeutic options.
• Berberine (Ber) possesses anti-inflammatory properties but suffers from poor solubility and bioavailability.
• Exosomes, particularly human placental mesenchymal stem cell-derived exosomes (HplMSC-Exos), offer a biocompatible drug delivery platform.

Purpose of the Study:

• To engineer exosomes loaded with berberine (Exos-Ber) for enhanced solubility and bioavailability.
• To evaluate the therapeutic potential of Exos-Ber for ulcerative colitis (UC) treatment.
• To investigate the anti-inflammatory and antioxidant mechanisms of Exos-Ber in UC.

Main Methods:

• Engineering of HplMSC-Exos loaded with berberine (Exos-Ber).
• In vitro and in vivo studies to assess antioxidant and anti-inflammatory properties.
• Evaluation of epithelial cell repair, apoptosis reduction, and MAPK signaling pathway modulation.

Main Results:

• Exos-Ber maintained structural and functional integrity similar to unmodified exosomes.
• Exos-Ber demonstrated significant in vitro and in vivo antioxidant and anti-inflammatory effects.
• Exos-Ber promoted epithelial cell repair, reduced apoptosis, and mitigated UC symptoms, potentially via MAPK pathway modulation.

Conclusions:

• Exos-Ber represents a novel and effective approach for delivering berberine for UC treatment.
• This nanocarrier system overcomes berberine's limitations, enhancing its clinical applicability.
• Exos-Ber shows significant therapeutic potential for alleviating ulcerative colitis.